Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ocumension Acquires Rights to Uveitis Drug in $12 Million Deal

publication date: Nov 6, 2018

Ocumension Therapeutics, a wholly owned subsidiary of Shanghai's 6 Dimensions Capital, entered a $11.75 million deal for greater China rights to EyePoint Medical's medical device that treats uveitis. The Durasert™ device, which is aimed specifically at chronic, non-infectious uveitis. is effective for three years. Ocumension will pay $1.75 million upfront and up to $10 million in milestones. In 2017, 6 Dimensions was formed by the merger of Frontline BioVentures and WuXi Healthcare Ventures. More details....

Stock Symbol: (NSDQ: EYPT)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
ChinaBio Partnering Forum 2019
Shanghai , China
May 8-9, 2019
 
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events